JW Pharmaceutical announced on Tuesday that it participated in the JP Morgan Healthcare Conference 2026, held in San Francisco from January 12-15. During the event, the company engaged in business development (BD) meetings with global pharmaceutical firms.
The JP Morgan Healthcare Conference is the world’s largest healthcare investment event, annually bringing together major pharmaceutical and biotech companies, as well as investment institutions from across the globe.
At this year’s conference, JW Pharmaceutical conducted numerous one-on-one meetings at the request of overseas pharmaceutical companies. These discussions centered on potential licensing deals and partnerships for key drug candidates, including:
• JW0061, a hair loss treatment candidate
• JW1601, an ophthalmic disease treatment
• An inflammatory disease treatment based on a STAT6 inhibitor
JW0061, a GFRA1 agonist being developed for conditions like androgenetic alopecia, recently secured U.S. patent registration. The company has also submitted an Investigational New Drug (IND) application to the Food and Drug Administration.
JW1601, initially developed as a histamine H4 receptor antagonist, has undergone a strategic pivot. The company has refocused its development efforts on ophthalmic diseases and is now preparing for Phase 2 clinical trials.
The STAT6 inhibitor is an oral first-in-class drug candidate targeting eosinophilic esophagitis (EoE) and other type 2 inflammatory diseases.
STAT6 has emerged as a novel mechanism of significant interest to the global pharmaceutical industry. Research and development efforts are intensifying, particularly for conditions with limited treatment options. This research project was selected for the National New Drug Development Program in 2025.
A spokesperson for JW Pharmaceutical emphasized the importance of the JP Morgan Healthcare Conference, saying it serves as a crucial platform for direct discussions on potential collaborations with global pharmaceutical companies. The spokesperson added that the company plans to leverage its R&D achievements to continue exploring global partnership opportunities.
